公开(公告)号：US20200317806A1

公开(公告)日：2020-10-08

申请号：US16838979

申请日：2020-04-02

申请人： Hoffmann-La Roche Inc. ,  Ludwig-Maximilians-Universitat Munchen

发明人： Carole Bourquin ,  Raffaella Castoldi ,  Stefan Endres ,  Christian Klein ,  Sebastian Kobold ,  Gerhard Niederfellner ,  Claudio Sustmann

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/32

摘要： The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an \JD antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor M specific antigen naturally occurring on the surface of a minor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors host cells, methods for the production of the (bispecific) antibody molecule as well as a kit comprising the (bispecific) antibody molecule of the invention.

公开(公告)号：US11732052B2

公开(公告)日：2023-08-22

申请号：US16838979

申请日：2020-04-02

申请人： Hoffmann-La Roche Inc. ,  Ludwig-Maximilians-Universitat Munchen

发明人： Carole Bourquin ,  Raffaella Castoldi ,  Stefan Endres ,  Christian Klein ,  Sebastian Kobold ,  Gerhard Niederfellner ,  Claudio Sustmann

IPC分类号： C07K16/30 ,  C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/32

CPC分类号： C07K16/30 ,  A61K39/001102 ,  A61K39/39558 ,  C07K16/2863 ,  C07K16/32 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/31 ,  Y02P20/582

摘要： Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.

公开(公告)号：US20150010567A1

公开(公告)日：2015-01-08

申请号：US14376364

申请日：2013-01-24

申请人： Hoffmann-La Roche Inc. ,  LUDWIG-MAXIMILLIANS-UNIVERSITÄT MÜNCHEN

发明人： Carole Bourquin ,  Raffaella Castoldi ,  Stefan Endres ,  Christian Klein ,  Sebastian Kobold ,  Gerhard Niederfellner ,  Claudio Sustmann

IPC分类号： C07K16/30 ,  A61K39/395 ,  A61K39/00 ,  C07K16/32

CPC分类号： C07K16/30 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/31 ,  Y02P20/582

摘要： The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor. The invention provides the use of said (bispecific) antibody molecules as a medicament, the (bispecific) antibody molecules for use in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said (bispecific) antibody molecules, wherein said (bispecific) antibody molecules are to be administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen. Further aspects of the invention are nucleic acid sequences encoding said bispecific (monoclonal) antibody molecules, vectors. host cells, methods for the production of the (bispecific) antibody molecule as well as a kit comprising the (bispecific) antibody molecule of the invention.

摘要翻译： 本发明涉及具有结合CD8 + T细胞上的抗原的第一结合结构域的双特异性（单克隆）抗体分子，其不天然存在于CD8 + T细胞和/或CD8 + T细胞中，和第二结合结构域结合肿瘤特异性抗原 天然存在于肿瘤细胞表面。 双特异性（单克隆）抗体分子特别可用于转导的CD8 + T细胞，其包含不天然存在于CD8 + T细胞和/或T细胞受体中的抗原。 本发明提供所述（双特异性）抗体分子作为药物的用途，用于治疗特定疾病的方法中的（双特异性）抗体分子以及包含所述（双特异性）抗体分子的药物组合物/药物，其中 所述（双特异性）抗体分子与转导的CD8 + T细胞组合施用，所述CD8 + T细胞在特异性治疗方案中包含不天然存在和/或在CD8 + T细胞和/或T细胞受体上的抗原。 本发明的其它方面是编码所述双特异性（单克隆）抗体分子，载体的核酸序列。 宿主细胞，（双特异性）抗体分子的制备方法以及包含本发明的（双特异性）抗体分子的试剂盒。